GlassScriptPhysician profile
Mary N Dotson
NPI 1508977240
$4,942.27
in general payments reported to CMS, 2019-2025
33 companies · $836 in 2025
The $836 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,066 · 2022: $1,139 · 2023: $1,067 · 2024: $835 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.16 |
| Education | $262.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,320.74 | 2021-2025 | |
| Janssen Biotech, INC. | $536.38 | 2021-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $379.34 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.66 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $301.25 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $267.34 | 2021-2025 | |
| Qol Medical, LLC | $213.01 | 2021-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $178.30 | 2022 | |
| Gilead Sciences, INC. | $157.08 | 2021-2024 | Epclusa |
| Pfizer INC. | $140.60 | 2021-2025 | |
| Celgene Corporation | $128.06 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $104.09 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $98.49 | 2022 | |
| Merck Sharp & Dohme LLC | $94.39 | 2021-2023 | Dificid |
| Redhill Biopharma INC. | $85.67 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $82.36 | 2021-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $70.21 | 2021-2023 | Rebyota |
| Intra-Sana Laboratories | $66.33 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $58.55 | 2024-2025 | Iqirvo, Bylvay |
| Amgen INC. | $58.02 | 2023 | Avsola, Amjevita |
| Braintree Laboratories, INC. | $45.59 | 2023-2024 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $34.98 | 2025 | Zenpep |
| Ethicon US, LLC | $28.54 | 2022 | |
| Mauna Kea Technologies, INC. | $24.62 | 2024 | |
| Celltrion USA INC. | $22.81 | 2024 | Zymfentra |
| Organon LLC | $19.86 | 2025 | Hadlima |
| Vivus LLC | $19.22 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.53 | 2024 | |
| Evoke Pharma, INC. | $17.34 | 2022 | |
| Alfasigma USA, INC. | $17.00 | 2021 | |
| Lilly USA, LLC | $15.24 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $14.41 | 2024 | Voquezna |
| Shield Therapeutics INC | $14.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dotson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.